HomeCompareORCC vs EW

ORCC vs EW: Dividend Comparison 2026

ORCC yields 9.79% · EW yields 2.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EW wins by $2.0K in total portfolio value· pulled ahead in Year 4
10 years
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →
EW
EW
● Live price
2.52%
Share price
$79.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.4K
Annual income
$295.93
Full EW calculator →

Portfolio growth — ORCC vs EW

📍 EW pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORCCEW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORCC + EW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORCC pays
EW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
EW
Annual income on $10K today (after 15% tax)
$213.84/yr
After 10yr DRIP, annual income (after tax)
$251.54/yr
At 15% tax rate, EW beats the other by $250.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORCC + EW for your $10,000?

ORCC: 50%EW: 50%
100% EW50/50100% ORCC
Portfolio after 10yr
$22.4K
Annual income
$148.48/yr
Blended yield
0.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EW right now

ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
EW
Analyst Ratings
32
Buy
16
Hold
Consensus: Buy
Price Target
$96.38
+21.2% upside vs current
Range: $87.00 — $110.00
Altman Z
10.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORCC buys
0
EW buys
0
No recent congressional trades found for ORCC or EW in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORCCEW
Forward yield9.79%2.52%
Annual dividend / share$1.32$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$21.4K$23.4K
Annual income after 10y$1.04$295.93
Total dividends collected$1.0K$2.8K
Payment frequencyquarterlyquarterly
SectorBDCHealthcare
Analyst consensusBuyBuy
Analyst price target$16.00$96.38

Year-by-year: ORCC vs EW ($10,000, DRIP)

YearORCC PortfolioORCC Income/yrEW PortfolioEW Income/yrGap
1$11,190$489.61$10,952$251.57+$238.00ORCC
2$12,229$256.01$11,976$257.49+$253.00ORCC
3$13,216$130.74$13,077$263.14+$139.00ORCC
4← crossover$14,207$66.02$14,261$268.55$54.00EW
5$15,234$33.17$15,533$273.70$299.00EW
6$16,317$16.62$16,899$278.61$582.00EW
7$17,468$8.32$18,365$283.28$897.00EW
8$18,695$4.16$19,938$287.72$1.2KEW
9$20,006$2.08$21,626$291.93$1.6KEW
10$21,407$1.04$23,436$295.93$2.0KEW

ORCC vs EW: Complete Analysis 2026

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →

EWHealthcare

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Full EW Calculator →
📬

Get this ORCC vs EW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORCC vs SCHDORCC vs JEPIORCC vs OORCC vs KOORCC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.